This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (20)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Raymond L. Woosley, MD, PhD

JAMA. 2000;284:3047-3049.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The article by Smalley et al¹ in this issue of THE JOURNAL presents yet another demonstration of the weaknesses in the US system for providing prescription medications to patients. The findings of Smalley et al¹ demonstrate the failure of efforts by the manufacturer of cisapride (Propulsid) to communicate to the health care community sufficiently to ensure optimal prescribing and dispensing of this drug. Smalley et al¹ reviewed the pharmacy files and demographic records of patients who were prescribed cisapride before and after labeling changes and warning letters were issued by the manufacturer.² These warnings called attention to new contraindicated uses of cisapride that could result in life-threatening ventricular arrhythmias. This study, a collaboration between 2 academic centers and the Food and Drug Administration (FDA), found that patients with contraindications for the use of cisapride continued to receive the drug at nearly the same rate after . . . [Full Text of this Article]

Author Affiliation: Department of Medicine, Georgetown University Medical Center, Washington, DC.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Contraindicated Use of Cisapride: Impact of Food and Drug Administration Regulatory Action
Walter Smalley, Deborah Shatin, Diane K. Wysowski, Jerry Gurwitz, Susan E. Andrade, Michael Goodman, K. Arnold Chan, Richard Platt, Stephanie D. Schech, and Wayne A. Ray
JAMA. 2000;284(23):3036-3039.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Reform of Drug Regulation -- Beyond an Independent Drug-Safety Board
Ray and Stein
NEJM 2006;354:194-201.
FULL TEXT  

A Search to Predict Potential for Drug-Induced Cardiovascular Toxicity
Hamlin
Toxicol Pathol 2006;34:75-80.
ABSTRACT | FULL TEXT  

Drug-Drug, Drug-Dietary Supplement, and Drug-Citrus Fruit and Other Food Interactions: What Have We Learned?
Huang and Lesko
J Clin Pharmacol 2004;44:559-569.
ABSTRACT | FULL TEXT  

Drug-Induced Prolongation of the QT Interval
Roden
NEJM 2004;350:1013-1022.
FULL TEXT  

Acute Congestive Heart Failure Induced by Rofecoxib
Campbell and Sneed
J Am Board Fam Med 2004;17:131-135.
FULL TEXT  

Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs From 2000 to 2002: First Results From the Research on Adverse Drug Events and Reports Project
Ladewski et al.
JCO 2003;21:3859-3866.
ABSTRACT | FULL TEXT  

Type 2 Diabetes Mellitus Induced by an Atypical Antipsychotic Medication
Sneed and Gonzalez
J Am Board Fam Med 2003;16:251-254.
FULL TEXT  

Evaluation of Prescribing Practices: Risk of Lactic Acidosis With Metformin Therapy
Calabrese et al.
Arch Intern Med 2002;162:434-437.
ABSTRACT | FULL TEXT